Astellas Pharma Inc. Website

Astellas Pharma Inc.

TSE-4503

Basic

  • Market Cap

    ¥2,983.77B

  • EV

    ¥3,627.21B

  • Shares Out

    1,793.13M

  • Revenue

    ¥1,603.67B

  • Employees

    14,754

Margins

  • Gross

    81.76%

  • EBITDA

    17.61%

  • Operating

    7.77%

  • Pre-Tax

    1.56%

  • Net

    1.06%

  • FCF

    8.38%

Returns (5Yr Avg)

  • ROA

    5.99%

  • ROTA

    16.75%

  • ROE

    9.57%

  • ROCE

    14.07%

  • ROIC

    10.05%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    ¥1,825.33

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    ¥364.47B

  • Net Debt

    ¥643.44B

  • Debt/Equity

    0.63

  • EBIT/Interest

    16.79

Growth (CAGR)

  • Rev 3Yr

    8.67%

  • Rev 5Yr

    4.19%

  • Rev 10Yr

    3.47%

  • Dil EPS 3Yr

    -47.35%

  • Dil EPS 5Yr

    -39.3%

  • Dil EPS 10Yr

    -13.5%

  • Rev Fwd 2Yr

    5.13%

  • EBITDA Fwd 2Yr

    42.8%

  • EPS Fwd 2Yr

    176.97%

  • EPS LT Growth Est

    91.83%

Dividends

  • Yield

    —

  • Payout

    736.46%

  • DPS

    ¥70

  • DPS Growth 3Yr

    18.56%

  • DPS Growth 5Yr

    13%

  • DPS Growth 10Yr

    10%

  • DPS Growth Fwd 2Yr

    6.01%

Select a metric from the list below to chart it

Mar '15

Mar '16

Mar '17

Mar '18

Mar '19

Mar '20

Mar '21

Mar '22

Mar '23

Mar '24

Mar '25 (E)

Mar '26 (E)

Mar '27 (E)

Metric
Mar '15
Mar '16
Mar '17
Mar '18
Mar '19
Mar '20
Mar '21
Mar '22
Mar '23
Mar '24

Total Revenues

1,300,843

1,249,528

1,296,163

1,518,619

1,603,672

Total Revenues % Chg.

-0.4%

-3.9%

3.7%

17.2%

5.6%

Cost of Goods Sold, Total

276,739

246,063

253,009

288,353

292,485

Gross Profit

1,024,104

1,003,465

1,043,154

1,230,266

1,311,187

Selling General & Admin Expenses, Total

499,295

504,316

548,840

630,272

740,110

R&D Expenses

224,226

224,489

246,010

276,128

294,187

Depreciation & Amortization

21,164

23,763

28,283

38,436

98,820

Other Operating Expenses

11,936

-35

1,876

53,778

53,464

Other Operating Expenses, Total

756,621

752,533

825,009

998,614

1,186,581

Operating Income

267,483

250,932

218,145

231,652

124,606

Interest Expense, Total

—

—

—

—

—

-2,232

-2,118

-2,315

-3,217

-7,423

Interest And Investment Income

2,248

760

862

5,253

8,851

Net Interest Expenses

16

-1,358

-1,453

2,036

1,428

Income (Loss) On Equity Invest.

-1,660

478

489

1,260

-3,165

Currency Exchange Gains (Loss)

-8,928

-2,332

8,172

-10,124

-807

Other Non Operating Income (Expenses)

1,342

72

-2,431

2,303

-1,723

EBT, Excl. Unusual Items

258,253

247,792

222,922

227,127

120,339

Restructuring Charges

—

—

-1,829

-9,293

-19,556

-4,510

-25,407

Gain (Loss) On Sale Of Investments

—

10,558

5,084

-5,007

-253

Gain (Loss) On Sale Of Assets

—

3,923

24

24,234

212

9,735

Asset Writedown

-13,796

-101,746

-74,850

-83,964

-78,931

Legal Settlements

—

—

-1,201

-2,012

-948

-1,497

-514

EBT, Incl. Unusual Items

245,350

145,323

156,886

132,361

24,969

Income Tax Expense

49,939

24,734

32,800

33,647

7,924

Earnings From Continuing Operations

195,411

120,589

124,086

98,714

17,045

Net Income

195,411

120,589

124,086

98,714

17,045

Net Income to Common Incl Extra Items

195,411

120,589

124,086

98,714

17,045

Net Income to Common Excl. Extra Items

195,411

120,589

124,086

98,714

17,045

Total Shares Outstanding

1,857.5

1,853

1,827.1

1,796.8

1,793.1

Weighted Avg. Shares Outstanding

1,876.2

1,857.1

1,849.7

1,820

1,793.3

Weighted Avg. Shares Outstanding Dil

1,877.5

1,858.2

1,850.6

1,825.1

1,799.7

EPS

104.2

64.9

67.1

54.2

9.5

EPS Diluted

104.1

64.9

67.1

54.1

9.5

EBITDA

333,879

323,584

297,829

337,390

282,446

Effective Tax Rate

20.4%

17%

20.9%

25.4%

31.7%